These Authors treated 12 HDV-CH patients with REP2139 500 ng intravenous QW for 15 weeks, followed by a 15-week treatment with REP2139 QW + peg-IFN-α-2a QW and finally by a 33-week treatment with peg-IFN-α-2a QW [131]. This evidence concerns the gene IFNA2 and cyclic hematopoiesis.